Stockreport

OptimizeRx: Q4 Earnings Report Indicates Caution For 2026 [Seeking Alpha]

OptimizeRx Corporation  (OPRX) 
NASDAQ:AMEX Investor Relations: optimizerx.com/investors
PDF Q4 2025 results beat estimates, but cautious 2026 guidance and only 2% expected revenue growth weigh on sentiment. High stock-based compensation gives the stock a hig [Read more]